Skip to content

PTC制药

US · PTCT #2071 按市值排名 上市于 1970
59.24 -1.75 -2.87%
实时 - 追踪5344个代码 - 心跳于509秒前 · 2026-10-16 19:30

✦ 量化股权信号 计算方式说明

减持
  • 最近一期（2026/Q3）披露持股的机构数量减少了1家。
  • 机构持股总比例下降了0.3个百分点。

机构持股

机构持股比例
122.07% -0.32pp
机构数量
465 -1
数据截至
2026/Q3 较上一报告期

持股变动 vs 资金流向

方向一致

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund91.52%
Hedge Fund19.18%
Public Company7.56%
Individual/Insider2.39%
Private Company2.01%
Government Pension Fund0.96%
Insurance Company0.55%
Family Office/Trust0.11%

主要股东 截至 2026-06-30

BlackRock 16.73% · 13.96M 股
RTW Investments, LP 9.28% · 7.75M 股
Janus Henderson Group plc 8.67% · 7.24M 股
Vanguard Portfolio Management, LLC 5.90% · 4.93M 股
State Street Global Advisors 5.51% · 4.60M 股
Vanguard Capital Management, LLC 5.18% · 4.33M 股
Wellington Management Group 4.95% · 4.13M 股
Geode Capital Management, LLC 2.64% · 2.21M 股
The Toronto-Dominion Bank 2.60% · 2.17M 股
Westfield Capital Management Company, L.P. 2.34% · 1.96M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 7次买入 · 40次卖出

姓名职务持股比例
Michael Schmertzler Independent Chairperson 1.74%
Matthew Klein Chief Executive Officer 0.19%
Mark Boulding Chief Legal Officer 0.13%
Christine Utter Senior VP, Chief Accounting Officer & Head of People Services 0.05%
Pierre Gravier Chief Financial Officer 0.04%
Lee Golden Chief Medical Officer 0.04%
Eric Pauwels Chief Business Officer 0.03%
Hege Sollie-Zetlmayer Officer 0.02%
Glenn Steele Independent Director 0.02%
Mary Smith Independent Director 0.02%

内部人交易 最近的 Form 4 申报记录

日期姓名职务类型股数价格
2026-10-04 Mark Boulding Chief Legal Officer Intent to Sell (Form 144) -1,638 $64.03
2026-09-29 Glenn Steele Independent Director Derivative Exercise and Sale -12,000 $11.23–65.16
2026-09-16 Michael Schmertzler Independent Chairperson Automatic Disposition -20,000 $66.58–68.45
2026-09-09 Michael Schmertzler Independent Chairperson Automatic Disposition -20,000 $67.34–68.67
2026-08-26 Michael Schmertzler Independent Chairperson Automatic Disposition -25,000 $71.55–73.18
2026-08-19 Michael Schmertzler Independent Chairperson Automatic Disposition -25,000 $70.78–73.67
2026-08-18 Michael Schmertzler Independent Chairperson Intent to Sell (Form 144) -50,000 --
2026-08-16 Mark Boulding Chief Legal Officer Derivative Exercise and Sale -2,813 $25.69–72.90
2026-08-03 Matthew Klein Chief Executive Officer Open Market Disposition -10,292 $68.57
2026-07-27 Hege Sollie-Zetlmayer Officer Other Acquisition +6,000 --
2026-07-27 Hege Sollie-Zetlmayer Officer Other Derivative Acquisition +5,213 $75.39
2026-07-27 Hege Sollie-Zetlmayer Officer Initial Statement of Beneficial 0 --
2026-07-13 Pierre Gravier Chief Financial Officer Open Market Disposition -3,494 $80.35
2026-07-08 Neil Almstead Chief Technical Operations Officer Derivative Exercise and Sale -2,464 $46.54–90.25
2026-07-08 Mary Smith Independent Director Derivative Exercise and Sale -15,834 $42.95–90.00
2026-07-06 Neil Almstead Chief Technical Operations Officer Derivative Exercise and Sale -46,774 $38.10–89.44
2026-07-06 Neil Almstead Chief Technical Operations Officer Intent to Sell (Form 144) -24,613 $88.88
2026-07-05 Mark Boulding Chief Legal Officer Derivative Exercise and Sale -5,079 $39.42–86.38
2026-07-05 Neil Almstead Chief Technical Operations Officer Intent to Sell (Form 144) -22,161 $86.00
2026-06-25 Neil Almstead Chief Technical Operations Officer Derivative Exercise and Sale -8,130 $38.10–85.26

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。

PTC制药 讨论区 0 条评论

发表评论